{ "Imdusiran (AB-729) for Chronic Hepatitis B", "This study is looking at how a drug called Imdusiran (AB-729) works in the liver of people with chronic hepatitis B. Researchers want to understand how much of the drug gets into the liver and how it affects the hepatitis B virus. You would receive four injections of Imdusiran, one every 8 weeks. You would also have two liver biopsies (small tissue samples taken from your liver): one when you get your first dose of Imdusiran, and another 8 weeks after your last dose. This study is for adults over 18 who are in good general health. Up to 10 people will participate in this study, which is currently recruiting.", "design": "This is a small, single-center study that is not randomized. It will include up to 10 adult participants.", "commitments": "You would receive 4 injections of Imdusiran over 24 weeks. You would also undergo 2 liver biopsies, with an optional third biopsy at week 52.", "compensation": "Not stated in the trial record.", "follow_up": "The study measures drug levels in the liver 8 weeks after the last dose of Imdusiran, and there is an optional liver biopsy at week 52.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.